Company profile
Stem Cell Authority, Ltd.
OTC: SCAL · Healthcare · Medical - Care Facilities
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 47
v0.1 · 5/100 weight · pillars only
↑ listing tenure, market scale · ↓ balance-sheet leverage, return on assets
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$4.2k
Employees
—
as of 2026-08-03
Market cap
$17.4k
as of 2026-08-03
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income-$4.2k-$4.2k2023
Operating income-$4.2k-$4.2k2023
Total assets$15$152002
Liabilities$80.5k$80.5k2002
Equity-$80.5k-$80.5k2002
Revenue trend
FY2001 – FY2023 · USD
FY01
FY02
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Stem Cell Authority, Ltd.’s revenue?
Stem Cell Authority, Ltd. booked $0 in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Pazoo, Inc.——Scopus BioPharma Inc.——Healthcare Solutions Management Group, Inc.——ARYx Therapeutics, Inc.——VioQuest Pharmaceuticals, Inc.——Golden Developing Solutions, Inc.——Neighbors
Summit →Key facts
CEOChong Yi Yang
SectorHealthcare
IndustryMedical - Care Facilities
HeadquartersFairlawn, OH
ExchangeOTC: SCAL
Employees—
IPO date2005-03-17
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.